Main Menu

This technology introduces a groundbreaking method for discovering and isolating anti-idiotypic antibodies, with a primary focus on inhibiting or extinguishing the activity of VRCOl, a broadly neutralizing anti-HIV-1 antibody. These anti-idiotypic antibodies provide a vital mechanism for controlling adverse events that may result from therapeutic antibody administration. The innovative method involves immunizing animals with specific antibody fragments, followed by systematic selection and isolation of somatically mutated B cells.

This groundbreaking technology introduces a highly potent, human anti-HIV antibody that targets a novel epitope, surpassing the efficacy of existing anti-HIV antibodies. With a prolonged half-life, it offers versatile applications, including early-stage HIV treatment, newborn prophylaxis, and vaccine development validation. Collaborative efforts aim to harness its potential for antibody-dependent cell-mediated cytotoxicity (ADCC) against HIV-infected cells.

The technology involves the development of monoclonal antibodies produced by hybridomas, including cell lines such as 10G3, 3E6, 10D4, 10G4, 1D8, 13D10, 9E5, and 9F10, which specifically react with Bacillus anthracis Lethal Factor (LF). These monoclonal antibodies offer valuable applications in anthrax detection, therapeutic intervention, and research into the biology of Bacillus anthracis and its lethal toxin. This advancement provides promising tools for mitigating the impact of anthrax infections and advancing our understanding of this deadly pathogen.

This technology includes 8 novel strains of the species Streptococcus mitis, Streptococcus oralis, and Streptococcus infantis for vaccine or probiotic development. The capsular biosynthetic genes from each of these strains are highly related to pneumococcal counterparts encoding 5 capsular serotypes. All 8 of these non-pneumococcal strains were recovered from nasopharyngeal (NP) or oropharyngeal (OP) specimens.

This technology includes a compound, CDEU050, which has shown to have anti-Ebola virus activity in cell culture. CDEU050 is a novel small molecule, unrelated to any previously described inhibitor that blocks Ebola virus infection in cell culture.

This technology includes using defective interfering (DI) genomes as a therapeutic against various mononegavirales. DI genomes are defective versions of the wildtype viral genome, incapable of replicating by itself but able to interfere with replication of the wildtype virus. We developed both a system to identify and characterize multiple naturally occurring henipaviruses Nipah (NiV) DI genomes species, and a methodology to artificially produce high titer stocks of virions containing these DI genomes, termed DI particles (DIPs).

This technology includes plasmodium falciparum parasites (PH1, Benin, FCQ79, Santa Lucia and Borneo) which have all been isolated from infected persons from various geographic locations and have been modified/adapted for growth in the laboratory for multiple uses. Plasmodium falciparum strain W2 is a parasite clone from a parasite isolate called Indochina III/CDC which in turn originated from a patient in Laos infected with chloroquine-resistant parasites. Gametocytes from W2 can be grown experimentally and used in experimental infection of chimpanzees and aotus monkeys.

This technology includes compositions useful as inhibitors of acetyltransferase Eis, whose upregulation causes kanamycin (KAN) resistance of tuberculosis (TB) infections, and therefore can be developed and utilized as a treatment for TB. In particular, the compositions are sulfonamide-based and sulfonyl isothiazole-based small molecules. Drug adjuvants in TB represent a conceptually novel approach to combatting a serious global epidemic of drug-resistant TB.

This technology includes methods for the delivery of active bacteriophages or other agents to the lung, with the goal of reducing bacterial colonization and improving clinical outcomes. This is accomplished by encapsulating, immobilizing, or otherwise incorporating bacteriophages to polymer particles in the micro- to nano-scale size range in order to target their delivery to specific lung regions. The current example of this involves poly(lactic-co-glycolic) acid (PLGA) particles conjugated to phages that kill Pseudomonas aeruginosa in the lungs of cystic fibrosis patients.

This technology includes a Dengue-2 isolated virus for use as a cancer vaccine therapeutic.